Abbott Laboratories closed 6.08% below its 52-week high of $141.23, which the company reached on March 4th.

Abbott Laboratories (NYSE: ABT) stock was in fine health on the second-to-last trading day of the week, thanks to news from ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Barclays analyst Matt Miksic maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of $158.00.

In a report released on March 27, Josh Jennings from TD Cowen reiterated a Buy rating on Abbott Laboratories (ABT – Research Report), with a ...

We recently published a list of the 10 Best S&P 500 Stocks to Buy for Dividend Growth. In this article, we are going to take ...

We recently published a list of Diamond Hill Capital Stock Portfolio: Top 10 Stock Picks. In this article, we are going to ...

We recently published a list of 10 Stocks Jump, Defy Market Uncertainties on Thursday. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other stocks ...

Abbott Laboratories closed 10.57% short of its 52-week high of $141.23, which the company reached on March 4th.

The company is first rolling out the use of the Volt system among European Union doctors who have already gained experience ...

Johnson & Johnson and Boston Scientific have also recently made moves to sell their own coronary intravascular lithotripsy ...